Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RGNX

RGNX - REGENXBIO Inc Stock Price, Fair Value and News

$11.02-2.39 (-17.82%)
Market Closed

46/100

RGNX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

46/100

RGNX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$13.47

Target 3M

$13.71

Target 6M

$13.62

RGNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGNX Price Action

Last 7 days

-26.6%

Last 30 days

-22.9%

Last 90 days

-14.0%

Trailing 12 Months

45%

RGNX RSI Chart

RGNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGNX Valuation

Market Cap

557.9M

Price/Earnings (Trailing)

-3.14

Price/Sales (Trailing)

3.46

EV/EBITDA

-2.46

Price/Free Cashflow

-5.25

RGNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$13.47

Target 3M

$13.71

Target 6M

$13.62

RGNX Fundamentals

RGNX Revenue

Revenue (TTM)

161.3M

Rev. Growth (Yr)

22.88%

Rev. Growth (Qtr)

39.21%

RGNX Earnings

Earnings (TTM)

-177.9M

Earnings Growth (Yr)

-3.93%

Earnings Growth (Qtr)

12.6%

RGNX Profitability

EBT Margin

-140.78%

Return on Equity

-110.2%

Return on Assets

-33.88%

Free Cashflow Yield

-19.05%

RGNX Investor Care

Shares Dilution (1Y)

2.18%

Diluted EPS (TTM)

-3.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025156.7M155.8M161.3M0
202486.7M89.0M84.3M83.3M
2023109.6M97.0M99.4M90.2M
2022473.7M484.3M480.0M112.7M
2021155.8M161.3M93.1M470.3M
202052.0M60.7M144.9M154.6M
2019172.7M126.9M81.1M35.2M
2018142.3M175.8M179.8M218.5M
20174.7M8.8M10.0M10.4M
20167.3M8.3M7.3M4.6M
20153.8M3.6M4.3M7.6M
20146.1M6.1M6.1M6.1M
20130006.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About REGENXBIO Inc

RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEregenxbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES401

REGENXBIO Inc Frequently Asked Questions

RGNX is the stock ticker symbol of REGENXBIO Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of REGENXBIO Inc is 557.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RGNX's fair value in chart for subscribers.

The fair value guage provides a quick view whether RGNX is over valued or under valued. Whether REGENXBIO Inc is cheap or expensive depends on the assumptions which impact REGENXBIO Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGNX.

As of Wed Jan 28 2026, RGNX's PE ratio (Price to Earnings) is -3.14 and Price to Sales (PS) ratio is 3.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGNX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, REGENXBIO Inc has provided -0.023 (multiply by 100 for percentage) rate of return.